IP Library › Granted Patent US 11,185,632
Granted Patent B2
US 11,185,632 · App. 16/808,816 · Granted Nov 30, 2021

Integrated insulin delivery system having safety features to prevent hypoglycemia

Inventors: Erwin S. Budiman (Fremont, CA); Gary A. Hayter (Oakland, CA); Nathan Crouther (Camarillo, CA); Marc B. Taub (Mountain View, CA); Wesley Scott Harper (Alameda, CA); Charles Wei (Fremont, CA)
Assignee: Abbott Diabetes Care, Inc.
A61M5/1723A61B5/1495A61B5/14532A61B5/4839G16H20/17A61B2562/0295A61M2005/14208A61M2005/14296A61M2205/3569A61M2205/52A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,185,632
App. No.
16/808,816
Filed
Mar 4, 2020
Granted
Nov 30, 2021
Kind
B2
Art Unit
3783
USPC
604/66
Abstract

Systems comprising: an analyte sensor for providing an analyte signal representative of an analyte level; a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose. Wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.

Claims (27)

1. A system comprising:

an analyte sensor for providing an analyte signal representative of an analyte level;

a controller in data communication with the analyte sensor and programmed to provide a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and

a model-based safety mechanism integrated with the controller for evaluating the recommended medication dose,

wherein the model-based safety mechanism overrides the recommended medication dose and provides a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.

2. The system of claim 1 , further comprising a medication delivery device for delivering medication to a user based on the recommended medication dose or the safety medication dose.

3. The system of claim 1 , wherein the user interface further allows the user to adjust the recommended medication dose, and wherein the safety mechanism overrides the adjusted recommended medication dose and provides the safety medication dose when the model-based safety mechanism detects the risk of insulin deprivation.

4. The system of claim 1 , wherein the sensed analyte is glucose and the medication type is one or more insulin types.

5. The system of claim 4 , wherein the one or more insulin types are selected from the group consisting of rapid acting insulin, long acting insulin, and any combination thereof.

6. The system of claim 1 , wherein the controller further provides a recommended medication delivery time and the model-based safety mechanism further overrides the recommended medication delivery time and provides a safety medication delivery time when the model-based safety mechanism detects the risk of insulin deprivation.

7. The system of claim 1 , wherein the model-based safety mechanism overrides the recommended medication dose based on at least a weighting between the analyte level and an estimated true analyte level.

8. The system of claim 1 , wherein the model-based safety mechanism stores delivered medication dose history.

9. The system of claim 8 , wherein the model-based safety mechanism detects the risk of insulin deprivation based at least on the stored delivered medication dose history.

10. The system of claim 1 , wherein the model-based safety mechanism stores insulin-on-board information.

11. The system of claim 1 , wherein an alert is provided on the user interface when the model-based safety mechanism detects the risk of insulin deprivation.

12. A method comprising:

sensing, using an analyte sensor, an analyte signal representative of an analyte level,

providing, using a controller in data communication with the analyte sensor, a recommended medication dose based on the analyte level and a medication type, the controller comprising a user interface for inputting the medication type; and

overriding, using a model-based safety mechanism integrated with the controller, the recommended medication dose and providing a safety medication dose when the model-based safety mechanism detects a risk of insulin deprivation.

13. The method of claim 12 , further comprising providing, using the controller, a delivery signal to a medication delivery device based on the recommended medication dose or the safety medication dose.

14. The method of claim 13 , further comprising delivering, using the medication delivery device, medication based on the recommended medication dose or the safety medication dose.

15. The method of claim 12 , further comprising permitting the user to adjust the recommended medication dose using the user interface, and wherein the overriding comprises overriding the adjusted recommended medication dose and providing the safety medication dose when the model-based safety mechanism detects the risk of insulin deprivation.

16. The method of claim 12 , wherein the sensed analyte is glucose and the medication type is one or more insulin types.

17. The method of claim 16 , wherein the one or more insulin types are selected from the group consisting of rapid acting insulin, long acting insulin, and any combination thereof.

18. The method of claim 12 , further comprising overriding, using the model-based safety mechanism, a recommended medication delivery time provided by the controller and providing a safety medication delivery time when the model-based safety mechanism detects the risk of insulin deprivation.

19. The method of claim 12 , wherein overriding the recommended medication dose is based on at least a weighting between the analyte level and an estimated true analyte level.

20. The method of claim 12 , further comprising storing, using the model-based safety mechanism, one or both of delivered medication dose history and insulin-on-board information.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2020
From: BUDIMAN, ERWIN S.; HAYTER, GARY A.; CROUTHER, NATHAN; TAUB, MARC B.; HARPER, WESLEY SCOTT; WEI, CHARLES
To: ABBOTT DIABETES CARE INC.
Reel/Frame 052012/0546 →
Continuity (6)
Continuation 16169350 · Oct 24, 2018
Continuation 14077181 · Nov 11, 2013
Division 13601944 · Aug 31, 2012
Division 12785104 · May 21, 2010
Provisional Application 61180627 · May 22, 2009
Related Publication 20200197607A1 · Jun 25, 2020
Cited By (1)
US 12,667,666